Karen Anderson, MD

Randomized Withdrawal Study Design to Evaluate the Persistence of the Therapeutic Effect of Deutetrabenazine in the Treatment of Tardive Dyskinesia

Mark Forrest Gordon , MD;

Amanda Wilhelm , PhD;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

10/08/2020

Background: The long-term open-label extension study of rollover subjects (n=343) from the ARM-TD and AIM-TD trials evaluating the safety and efficacy of deutetrabenazine for the treatmen...

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Long-Term Treatment With Deutetrabenazine Is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

Mark Forrest Gordon , MD;

Maria Wieman , MPH;

Mat Davis , PhD;

Leslie Marinelli , BS;

11/22/2019

BACKGROUND: In the 12-week ARM-TD and AIM-TD studies of patients with tardive dyskinesia (TD), the percentage of patients achieving ≥50% and ≥70% responses (i.e. reductions from baseline ...

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Nicholas Gross , MS;

Stewart Factor , DO;

Effect of Deutetrabenazine on Metabolic Parameters in the Treatment of Tardive Dyskinesia

Karen Anderson , MD;

11/22/2019

BACKGROUND: Deutetrabenazine, a novel vesicular monoamine transporter 2 (VMAT2) inhibitor, is approved by the FDA for treatment of tardive dyskinesia (TD) in adults. Dopamine-receptor ant...

Maria Wieman , MPH;

Karen Anderson , MD;

Hubert Fernandez , MD;

Hadas Barkay , PhD;

Long-Term Deutetrabenazine Treatment Response in Tardive Dyskinesia by Concomitant Dopamine-Receptor Antagonists and Baseline Comorbidities

Mark Forrest Gordon , MD;

Stewart Factor , DO;

11/22/2019

Background: Tardive dyskinesia (TD) is managed by dose reduction or interruption of dopamine-receptor antagonists (DRAs), possibly causing psychiatric disorder relapse. Deutetrabenazine (...

Mat Davis , PhD;

David Stamler , MD;

Long-term Improvements in Site-Rated Outcomes With Deutetrabenazine Treatment in Patients With Tardive Dyskinesia

Fredrick Jarskog , MD;

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Karen Anderson , MD;

Joseph McEvoy , MD;

Hubert Fernandez , MD;

Stanislaw Ochudlo , MD, PhD;

03/01/2019

Background: Tardive dyskinesia (TD) is a movement disorder that may intensify the stigma of patients with psychiatric disorders. In the ARM-TD and AIM-TD trials (parent studies), deutetra...

Nicholas Gross , MS;

Mat Davis , PhD;

David Stamler , MD;

Long-Term Treatment With Deutetrabenazine is Associated With Continued Improvement in Tardive Dyskinesia (TD): Results From an Open-Label Extension Study

Rajeev Kumar , MD, FRCPC, CMD, FACP;

Joseph McEvoy , MD;

Fredrick Jarskog , MD;

Karen Anderson , MD;

Stanislaw Ochudlo , MD, PhD;

Hubert Fernandez , MD;

03/01/2019

Background: In the 12-week ARM-TD and AIM-TD studies, the odds of response to deutetrabenazine treatment were higher than the odds of response to placebo at all response levels. Deutetrab...

Hubert Fernandez , MD;

Stewart Factor , DO;

Mat Davis , PhD;

David Stamler , MD;

Confirmed Safety of Deutetrabenazine for Tardive Dyskinesia in a 2-Year Open-Label Extension Study

William Ondo , MD;

Fredrick Jarskog , MD;

Scott Woods , MD;

Mark LeDoux , MD, PhD;

David Shprecher , DO, MS;

Karen Anderson , MD;

03/01/2019

Background: Deutetrabenazine was efficacious and safe in treating tardive dyskinesia (TD) in the 12-week ARM-TD and AIM-TD studies. Objective: To evaluate the long-term safety and tolerab...

Mat Davis , PhD;

David Stamler , MD;